Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Cost-effectiveness analysis of fluticasone versus montelukast in children with mild-to-moderate persistent asthma in the Pediatric Asthma Controller Trial.

Wang L, Hollenbeak CS, Mauger DT, Zeiger RS, Paul IM, Sorkness CA, Lemanske RF Jr, Martinez FD, Strunk RC, Szefler SJ, Taussig LM; Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute.

J Allergy Clin Immunol. 2011 Jan;127(1):161-6, 166.e1. doi: 10.1016/j.jaci.2010.10.035.

2.

Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma.

Sheth K, Borker R, Emmett A, Rickard K, Dorinsky P.

Pharmacoeconomics. 2002;20(13):909-18.

PMID:
12381242
3.

Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma.

O'Connor RD, Nelson H, Borker R, Emmett A, Jhingran P, Rickard K, Dorinsky P.

Pharmacoeconomics. 2004;22(12):815-25.

PMID:
15294013
4.

Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial.

Sorkness CA, Lemanske RF Jr, Mauger DT, Boehmer SJ, Chinchilli VM, Martinez FD, Strunk RC, Szefler SJ, Zeiger RS, Bacharier LB, Bloomberg GR, Covar RA, Guilbert TW, Heldt G, Larsen G, Mellon MH, Morgan WJ, Moss MH, Spahn JD, Taussig LM; Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute.

J Allergy Clin Immunol. 2007 Jan;119(1):64-72. Epub 2006 Nov 30. Erratum in: J Allergy Clin Immunol. 2007 Aug;120(2):285.

PMID:
17140647
5.

[Cost effectiveness of treatment with salmeterol/fluticasone compared to montelukast for the control of persistent asthma in children].

Rely K, McQuire SE, Alexandre PK, Escudero GS.

Value Health. 2011 Jul-Aug;14(5 Suppl 1):S43-7. doi: 10.1016/j.jval.2011.05.033. Spanish.

6.
7.

Salmeterol/fluticasone propionate versus fluticasone propionate plus montelukast: a cost-effective comparison for asthma.

Pieters WR, Wilson KK, Smith HC, Tamminga JJ, Sondhi S.

Treat Respir Med. 2005;4(2):129-38.

PMID:
15813665
8.

Asthma-related health care resource use among patients starting fluticasone or montelukast therapy.

Allen-Ramey FC, Anstatt DT, Sajjan SG, Markson LE.

Pharmacotherapy. 2005 Dec;25(12):1752-60.

PMID:
16305295
10.

Asthma hospitalization risk and costs for patients treated with fluticasone propionate vs montelukast.

Orsini L, Limpa-Amara S, Crown WH, Stanford RH, Kamal K.

Ann Allergy Asthma Immunol. 2004 May;92(5):523-9.

PMID:
15191020
11.
12.

Characterization of within-subject responses to fluticasone and montelukast in childhood asthma.

Szefler SJ, Phillips BR, Martinez FD, Chinchilli VM, Lemanske RF, Strunk RC, Zeiger RS, Larsen G, Spahn JD, Bacharier LB, Bloomberg GR, Guilbert TW, Heldt G, Morgan WJ, Moss MH, Sorkness CA, Taussig LM.

J Allergy Clin Immunol. 2005 Feb;115(2):233-42.

PMID:
15696076
13.

Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast.

Stempel DA, Mauskopf J, McLaughlin T, Yazdani C, Stanford RH.

Respir Med. 2001 Mar;95(3):227-34.

14.

Outcomes associated with initiation of different controller therapies in a Medicaid asthmatic population: a retrospective data analysis.

Balkrishnan R, Nelsen LM, Kulkarni AS, Pleasants RA, Whitmire JT, Schechter MS.

J Asthma. 2005 Feb;42(1):35-40.

PMID:
15801326
15.

Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs.

O'Connor RD, Stanford R, Crim C, Yancey SW, Edwards L, Rickard KA, Dorinsky P.

Ann Allergy Asthma Immunol. 2004 Dec;93(6):581-8.

PMID:
15609769
16.

Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma.

Ostrom NK, Decotiis BA, Lincourt WR, Edwards LD, Hanson KM, Carranza Rosenzweig JR, Crim C.

J Pediatr. 2005 Aug;147(2):213-20.

PMID:
16126052
17.

Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma.

Zeiger RS, Szefler SJ, Phillips BR, Schatz M, Martinez FD, Chinchilli VM, Lemanske RF Jr, Strunk RC, Larsen G, Spahn JD, Bacharier LB, Bloomberg GR, Guilbert TW, Heldt G, Morgan WJ, Moss MH, Sorkness CA, Taussig LM; Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute.

J Allergy Clin Immunol. 2006 Jan;117(1):45-52.

PMID:
16387583
18.

Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene modifier therapies in pediatric asthma.

Knuffman JE, Sorkness CA, Lemanske RF Jr, Mauger DT, Boehmer SJ, Martinez FD, Bacharier LB, Strunk RC, Szefler SJ, Zeiger RS, Taussig LM; Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute.

J Allergy Clin Immunol. 2009 Feb;123(2):411-6. doi: 10.1016/j.jaci.2008.11.016. Epub 2009 Jan 3.

19.

Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma.

Lyseng-Williamson KA, Plosker GL.

Pharmacoeconomics. 2003;21(13):951-89. Review.

PMID:
12959627
20.

Short-term and long-term asthma control in patients with mild persistent asthma receiving montelukast or fluticasone: a randomized controlled trial.

Zeiger RS, Bird SR, Kaplan MS, Schatz M, Pearlman DS, Orav EJ, Hustad CM, Edelman JM.

Am J Med. 2005 Jun;118(6):649-57.

PMID:
15922697

Supplemental Content

Support Center